Hepatitis C virus infection in nonliver solid organ transplant candidates and recipients

Current Opinion in Organ Transplantation

Volumn 20, Issue 3, 2015, Pages 259-266

  Aqel, Bashar A ^a   Vargas, Hugo E ^a  

^a MAYO CLINIC   (United States)

Author keywords

Direct acting antiviral agents; End stage kidney disease; Hemodialysis; Hepatitis C; Solid organ transplant

Indexed keywords

ANTIVIRUS AGENT; DIRECT ACTING ANTIVIRAL; UNCLASSIFIED DRUG;

ANTIVIRAL THERAPY; CHRONIC HEPATITIS C; END STAGE RENAL DISEASE; ESTIMATED GLOMERULAR FILTRATION RATE; HEART TRANSPLANTATION; HEMODIALYSIS; HEPATITIS C; HUMAN; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LUNG TRANSPLANTATION; MODERATE RENAL IMPAIRMENT; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; SEVERE RENAL IMPAIRMENT; DONOR; GRAFT RECIPIENT; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; HEPATITIS C; HUMANS; ORGAN TRANSPLANTATION; TISSUE DONORS; TRANSPLANT RECIPIENTS; TREATMENT OUTCOME;

EID: 84990992970     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000195     Document Type: Review

References (44)

1. Smith BD, Morgan RL, Beckett GA, et al. Hepatitis C virus testing of persons born during 1945–1965: recommendations from the Centers for Disease Control and Prevention. Ann Intern Med 2012; 157:817–822.
2. Younossi ZM, Kanwal F, Saab S, et al. The impact of hepatitis C burden: an evidence-based approach. Aliment Pharmacol Ther 2014; 39:518–531.
3. El-Serag HB, Anand B, Richardson P, Rabeneck L. Association between hepatitis C infection and other infectious diseases: a case for targeted screening? Am J Gastroenterol 2003; 98:167–174.
4. Davis GL, Alter MJ, El-Serag H, et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138:513–521.
5. Smith BD, Jorgensen C, Zibbell JE, Beckett GA. Centers for Disease Control and Prevention initiatives to prevent hepatitis C virus infection: a selective update. Clin Infect Dis 2012; 55 (Suppl 1):S49–S53.
6. Jacobson IM, Davis GL, El-Serag H, et al. Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 2010; 8:924–933.
7. Su Y, Norris JL, Zang C, et al. Incidence of hepatitis C virus infection in patients on hemodialysis: a systematic review and meta-analysis. Hemodial Int 2013; 17:532–541.
8. Baid-Agrawal S, Pascual M, Moradpour D, et al. Hepatitis C virus infection in haemodialysis and kidney transplant patients. Rev Med Virol 2008; 18:97–115.
9. Gallagher M, Langham R, Craig J, Walker R. KDIGO hepatitis C guideline: implications for regional guideline development and implementation. Nephrology (Carlton) 2009; 14:281–282.
10. Fabrizi F, Martin P, Dixit V, et al. Meta-analysis: Effect of hepatitis C virus infection on mortality in dialysis. Aliment Pharmacol Ther 2004; 20:1271–1277.
11. Goodkin DA, Bragg-Gresham JL, Koenig KG, et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 2003; 14:3270–3277.
12. Fabrizi F, Takkouche B, Lunghi G, et al. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. J Viral Hepat 2007; 14:697–703.
13. Fabrizi F, Lunghi G, Ganeshan SV, et al. Hepatitis C virus infection and the dialysis patient. Semin Dial 2007; 20:416–422.
14. Swain MG, Lai MY, Shiffman ML, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010; 139:1593–1601.
15. Manns MP, Pockros PJ, Norkrans G, et al. Long-term clearance of hepatitis C virus following interferon alpha-2b or peginterferon alpha-2b, alone or in combination with ribavirin. J Viral Hepat 2013; 20:524–529.
16. Feld JJ, Jacobson IM, Jensen DM, et al. Randomized study of danoprevir/ & ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin. J Hepatol 2015; 62:294–302. This study shows the excellent response that can be achieved using one of the all-oral IFN-free regimens in patients who failed prior treatment.
17. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483–1493.
18. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370:1889–1898.
19. Sulkowski MS, Jacobson IM, Nelson DR. Daclatasvir plus sofosbuvir for HCV & infection. N Engl J Med 2014; 370:1560–1561. This study shows outcomes achieved by combining two DAAs with excellent safety profile and high rates of efficacy. The regimen allows the elimination of RBV making this regimen suitable post-solid organ transplant.
20. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or & without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in nonresponders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384:1756–1765. The efficacy of the combination of simeprevir and sofosbuvir without RBV allows its use both after and before solid organ transplant with high rates of sustained virological response.
21. Huraib S, Tanimu D, Romeh SA, et al. Interferon-alpha in chronic hepatitis C infection in dialysis patients. Am J Kidney Dis 1999; 34:55–60.
22. Kamar N, Chatelut E, Manolis E, et al. Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function. Am J Kidney Dis 2004; 43:140–146.
23. Werner T, Aqel B, Balan V, et al. Treatment of hepatitis C in renal transplantation candidates: a single-center experience. Transplantation 2010; 90:407–411.
24. Tseng PL, Chen TC, Chien YS, et al. Efficacy and safety of pegylated && interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts. Am J Kidney Dis 2013; 62:789–795.
25. This study outlines the challenges we faced treating patients with ESKD with IFN-based regimens. Treatment is long, less effective, and accompanied by high dropout rates and adverse events.
26. Saadoun D, Resche Rigon M, Pol S, et al. PegIFNalpha/ribavirin/protease & inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis. J Hepatol 2015; 62:24–30.
27. This study outlines the outcome using the first-generation PIs combined with pegylated IFN and RBV to treat HCV in patients with kidney disease. SVR rates were high but regimen was associated with high rates of serious adverse events (46.6%). Regimen was poorly tolerated in patients with advanced fibrosis.
28. Vierling JM, Davis M, Flamm S, et al. Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response. J Hepatol 2014; 60:748–756.
29. Saadoun D, Resche Rigon M, Thibault V, et al. Peg-IFNalpha/ribavirin/pro- & tease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. Ann Rheum Dis 2014; 73:831–837. Another study reporting outcome of the use of first-generation PIs combined with pegylated IFN and RBV in patients with kidney disease. High rates of serious adverse events accompanied by high dropout rate (34.7%) limits the ability of its use in patients awaiting kidney transplant.
30. Baid-Agrawal S, Pascual M, Moradpour D, et al. Hepatitis C virus infection && and kidney transplantation in 2014: what’s new? Am J Transplant 2014; 14:2206–2220. This article is a very comprehensive up-to-date review of impact of HCV infection on patients with ESKD both before and after kidney transplant. It offers an assessment of the multiple treatment regimens available and several proposals regarding optimal timing of HCV treatment, criteria for combined listing for transplant, and criteria for the use of HCV-positive kidneys.
31. Kim E, Ko HH, Yoshida EM. Treatment issues surrounding hepatitis C in renal transplantation: a review. Ann Hepatol 2011; 10:5–14.
32. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r- & ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370:1604–1614. This study outlines the high SVR rates with one of the currently available FDA-approved regimens to treat HCV genotype-1 infection. This regimen has the potential use in patients with kidney disease.
33. Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for && HCV after liver transplantation. N Engl J Med 2014; 371:2375–2382. This study showed that this all-oral IFN-free regimen can be used post-liver transplant with high rate of SVR. This regimen can be associated with significant drug–drug interactions with calcineurin inhibitors and will require close monitoring of drug levels and may limit its wide use post-solid organ transplant.
34. Cano O, Almenar L, Martinez-Dolz L, et al. Course of patients with chronic hepatitis C virus infection undergoing heart transplantation. Transplant Proc 2007; 39:2353–2354.
35. Lee I, Localio R, Brensinger CM, et al. Decreased posttransplant survival among heart transplant recipients with pretransplant hepatitis C virus positivity. J Heart Lung Transplant 2011; 30:1266–1274.
36. Fong TL, Hou L, Hutchinson IV, et al. Impact of hepatitis C infection on outcomes after heart transplantation. Transplantation 2009; 88:1137–1141.
37. Kim EY, Ko HH, Yoshida EM. A concise review of hepatitis C in heart and lung transplantation. Can J Gastroenterol 2011; 25:445–448.
38. Fagiuoli S, Minniti F, Pevere S, et al. HBV and HCV infections in heart transplant recipients. J Heart Lung Transplant 2001; 20:718–724.
39. Poordad FF, Fabrizi F, Martin P. Hepatitis C infection associated with renal disease and chronic renal failure. Semin Liver Dis 2004; 24 (Suppl 2):69–77.
40. Haji SA, Starling RC, Avery RK, et al. Donor hepatitis-C seropositivity is an independent risk factor for the development of accelerated coronary vasculopathy and predicts outcome after cardiac transplantation. J Heart Lung Transplant 2004; 23:277–283.
41. Gasink LB, Blumberg EA, Localio AR, et al. Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients. J Am Med Assoc 2006; 296:1843–1850.
42. Ong JP, Barnes DS, Younossi ZM, et al. Outcome of de novo hepatitis C virus infection in heart transplant recipients. Hepatology 1999; 30:1293–1298.
43. Carbone M, Mutimer D, Neuberger J. Hepatitis C virus and nonliver solid && organ transplantation. Transplantation 2013; 95:779–786. This represent one of the few comprehensive reviews that address the impact and management of HCV in the setting of solid organ transplant other than liver transplantation.
44. Fong TL, Cho YW, Hou L, et al. Outcomes after lung transplantation and practices of lung transplant programs in the United States regarding hepatitis C seropositive recipients. Transplantation 2011; 91:1293–1296.